TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06422923: A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)

Sponsor: Neurona Therapeutics · Phase: PHASE1/PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$1,978,800

Rescue Site Savings

+$1,319,200

Unlock Full NCT06422923 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06422923 Rescue Dossier →